Investors

Where Innovation Meets Impact.

AI-Powered Platforms Transforming Digital Health and Driving Shareholder Value

Why Invest in AIML?

We are pioneering the future of health intelligence by developing and commercializing advanced AI-driven technologies that unlock powerful biometric insights

Backed by a growing portfolio of proprietary technologies and a world-class leadership team, AIML is committed to delivering long-term value to shareholders while improving health outcomes across global markets.

September 4, 2025

AIML Announces Proposed Private Placement

September 4, 2025
AIML Announces Proposed Private Placement
Read More
August 21, 2025
AIML Announces SEDAR Filing
Read More
August 8, 2025
AIML Innovations Closes Quantum Sciences Ltd. Restructuring
Read More
June 10, 2025
AIML Strengthens IP Portfolio with Provisional Patents for AI Driven ECG Signal Processing
Read More
June 3, 2025
AIML Subsidiary Neural Cloud Signs LOI with Circular Health to License MaxYield™ ECG Signal-Processing
Read More
May 22, 2025
AIML Establishes Innovation Committee, Appoints Dr. Drew Dundas as Chair
Read More
Corporate Governance
Board of Directors

Paul Duffy

Executive Chairman and CEO

Dr. Drew Dundas

Independent Director

Jared Adelstein

Independent Director

Peter Kendall

Director and CCO

Michael Diamond

Independent Director
Financials

Read more on CSE

AGM Materials
Information Circular
Notice and Access
Form of Proxy
Financial Request Form
Information Circular
Notice and Access
Form of Proxy & Return Card
Notice of Meeting and Information Circular
Form of Proxy and Return Card

Historic AGM materials can be found under the company’s profile on SEDAR+

Charters & Policies
Corporate Disclosure and Insider Trading Policy
Code of Business Conduct and Ethics
Audit Committee Charter
Whistleblower Policy
Company Structure
215.2
Million
Shares Outstanding
9.95
Million
Options
154.7
Million
Warrants Outstanding
379.8
Million
Fully Diluted